Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Total psoriasis regression in a patient with chronic myeloid leukemia treated using nilotinib

T. Horňák, D. Žáčková, J. Mayer

. 2025 ; 104 (3) : 2001-2004. [pub] 20250228

Jazyk angličtina

Typ dokumentu kazuistiky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25016373

Chronic myeloid leukemia (CML) treatment has been revolutionized over last 20 years because of tyrosine kinase inhibitors (TKIs) and patients with CML now have life expectancy of general population. Chronic TKI treatment may cause adverse effects (AEs) that vary in frequency and severity. Nilotinib shows common AEs with metabolic changes and skin AEs. Here, we present a case report of patient who experienced full psoriasis regression while treated with nilotinib. Dose reductions and an attempt to stop nilotinib treatment resulted in prompt psoriasis reappearance. This is the first documented case of positive effect of nilotinib on psoriasis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25016373
003      
CZ-PrNML
005      
20250731092847.0
007      
ta
008      
250708s2025 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00277-025-06228-x $2 doi
035    __
$a (PubMed)40016401
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a x
100    1_
$a Horňák, Tomáš $u Department of Internal Medicine Hematology and Oncology, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czech Republic
245    10
$a Total psoriasis regression in a patient with chronic myeloid leukemia treated using nilotinib / $c T. Horňák, D. Žáčková, J. Mayer
520    9_
$a Chronic myeloid leukemia (CML) treatment has been revolutionized over last 20 years because of tyrosine kinase inhibitors (TKIs) and patients with CML now have life expectancy of general population. Chronic TKI treatment may cause adverse effects (AEs) that vary in frequency and severity. Nilotinib shows common AEs with metabolic changes and skin AEs. Here, we present a case report of patient who experienced full psoriasis regression while treated with nilotinib. Dose reductions and an attempt to stop nilotinib treatment resulted in prompt psoriasis reappearance. This is the first documented case of positive effect of nilotinib on psoriasis.
650    _2
$a lidé $7 D006801
650    12
$a chronická myeloidní leukemie $x farmakoterapie $x komplikace $7 D015464
650    12
$a inhibitory proteinkinas $x terapeutické užití $x škodlivé účinky $x aplikace a dávkování $7 D047428
650    12
$a psoriáza $x farmakoterapie $x komplikace $x chemicky indukované $x patologie $7 D011565
650    12
$a pyrimidiny $x terapeutické užití $x škodlivé účinky $x aplikace a dávkování $7 D011743
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
700    1_
$a Žáčková, Daniela $u Department of Internal Medicine Hematology and Oncology, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czech Republic. Zackova.Daniela@fnbrno.cz $1 https://orcid.org/0000000198028148 $7 xx0074334
700    1_
$a Mayer, Jiří $u Department of Internal Medicine Hematology and Oncology, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czech Republic
773    0_
$w MED00000424 $t Annals of hematology $x 1432-0584 $g Roč. 104, č. 3 (2025), s. 2001-2004
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40016401 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731092842 $b ABA008
999    __
$a ok $b bmc $g 2366906 $s 1253498
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 104 $c 3 $d 2001-2004 $e 20250228 $i 1432-0584 $m Annals of hematology $n Ann Hematol $x MED00000424
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace